logo-loader
viewFrontier IP Group PLC

Frontier IP’s Exscientia begins clinical trial for world’s first AI-created drug

The DSP-1181 drug, created as part of a joint development agreement with Japanese firm Sumitomo Dainippon Pharma, is designed to treat OCD

Frontier IP Group PLC - Frontier IP’s Exscientia begins clinical trial for world’s first AI-created drug

Frontier IP Group PLC’s (LON:FIPP) portfolio firm, Exscientia, has begun phase 1 clinical trials of DSP-1181, the world’s first drug created by artificial intelligence (AI).

The drug, created as part of a joint development agreement with Japanese firm Sumitomo Dainippon Pharma, is designed to treat obsessive compulsive disorder (OCD).

READ: Frontier IP delighted with first funding round for The Vaccine Group

Exscientia said the project had been delivered by a “strong synergy” of research between the two companies, requiring less than 12 months to complete the exploratory research phase as opposed to the typical average of 4.5 years using conventional research techniques.

"We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery”, said Exscientia chief executive Andrew Hopkins.

“We are proud that our AI drug discovery platform Centaur Chemist has contributed to generate DSP-1181 and look forward to its progression as a treatment for obsessive-compulsive disorder", he added.

Quick facts: Frontier IP Group PLC

Price: 63.85 GBX

AIM:FIPP
Market: AIM
Market Cap: £32.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Frontier IP 'in strong position' and working closely with portfolio...

Frontier IP Group PLC's (LON:FIPP) Neil Crabb speaks to Proactive London's Andrew Scott to discuss how the Intellectual property specialist's portfolio companies are adapting to the new virus threat. Crabb also touches on new investee company Elute Intelligence, in which it holds a 43% stake,...

1 day, 9 hours ago

2 min read